# Veterinary_Nutraceuticals_Plan_Slides.pptx

## Slide 1

### Veterinary Nutraceuticals – Strategic Overview

Market Structure, Scientific Evidence, Value Chain, Growth and Investment Themes
December 2025

## Slide 2

### Market Definition and Scope

• Definition spectrum: nutraceutical vs supplement vs zootechnical additive
• In/out-of-scope product classes (e.g. oral, non-drug, non-commodity)
• Human vs veterinary: WTP divergence, regulatory friction

## Slide 3

### Functional Segmentation and Species Needs

• Functional areas: Joint, Gut, Immune, Calming, Cognitive, Performance
• Species focus: Dogs, Cats, Poultry, Swine, Horses, Aquaculture
• Drivers: aging, AGP bans, value per kg, preventive care

## Slide 4

### Scientific Evidence and Adoption

• Evidence ranking: Omega-3 > Probiotics > Botanicals > Glucosamine
• Format realities: chews (dogs), premix (swine), feed-inclusion (fish)
• Regulatory divergence: GRAS in US, EFSA in EU

## Slide 5

### Market Size and Growth

• Pet nutraceuticals: ~$6.8B in 2023, 6–8% CAGR
• Livestock feed additives: ~$24B, 4–6% CAGR
• APAC leading growth, US largest market, EU most regulated

## Slide 6

### Value Chain and Margins

• Layers: Ingredients → Premix → Feed/Formulator → Brand
• Margin stack: DTC/brands > Vet > Ingredient > Premix
• EBITDA examples: Zesty Paws (70%), Ingredient Blenders (10–15%)

## Slide 7

### Competitive Landscape

• Players: DSM, Evonik, Nutramax, Zoetis, Native Pet
• Fragmentation vs barriers: DTC low, EFSA high
• Channel control: vet endorsement, DTC brand equity

## Slide 8

### Investment Themes and Risks

• Opportunity map: Calming, Gut Health, Aquaculture Postbiotics
• Risks: Evidence gaps, Regulatory tightening, Channel consolidation
• Strategies: Brand rollups, Ingredient IP plays, Veterinary channels

